There are two errors in this paper by Tsague & Abrams [1] .
In Table 1 on page S120, the regimen in the first column on the 4th row should read 'tenofovir þ lamivudine (or emtricitabine) þ efavirenz', instead of 'tenofovir þ lamivudine/efavirenz þ emtracitabine'. The text should read:
'First-line ART should consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reversetranscriptase inhibitor (NNRTI) tenofovir þ lamivudine (or emtricitabine) þ efavirenz'as a fixed-dose combination, (FDC) is recommended option for ART initiation'
In the last sentence of the second paragraph on page S120, the drug name Emtricitabine should have been Efavirenz. The text should read:
'Efavirenz was further preferred over nevirapine given concerns about the increased risk of maternal hepatotoxicity of nevirapine in this group [14, 15] .'
